On January 15, trading data showed AbbVie call-option volume surged by 2,599% versus its 30-day average, as professional and institutional investors placed high-conviction bullish wagers in the weeks before the company’s clinical readout. Open interest in near-term strikes expiring in February rose from approximately 3,200 contracts to over 85,000 contracts within two sessions. The notional value of these commitments exceeded $400 million, suggesting expectations of material share appreciation tied to anticipated regulatory updates or trial results. This options flow preceded AbbVie’s January 16 announcement of Phase 3 data, indicating that sophisticated market participants positioned ahead of public disclosure, and underscores the importance of monitoring derivatives markets for early signals of corporate catalysts.

AbbVie and partner Genmab today disclosed that the globally enrolled Phase 3 EPCORE® DLBCL-1 trial in relapsed/refractory diffuse large B-cell lymphoma achieved a progression-free survival hazard ratio of 0.74 (95% CI: 0.60–0.92) versus investigator’s choice chemoimmunotherapy, representing a 26% risk reduction. Among 483 patients (73% with two or more prior lines), epcoritamab produced a higher complete response rate and extended median duration of response by nearly four months compared with standard regimens. While overall survival difference was not statistically significant (HR: 0.96; 95% CI: 0.77–1.20), safety profiles aligned with known cytokine release and cytopenia risks, and no new adverse signals emerged. AbbVie plans regulatory submissions in the first half of 2026 and intends to present full data at an upcoming hematology congress, positioning epcoritamab for potential market entry in a segment that sees roughly 25,000 new U.S. cases annually.